CELADRIN®-PURE | Joint Health (90 Capsules)

CELADRIN®-PURE, an effective and natural, joint and muscle support.

• Innovative & proprietary cetylated fatty acid complex from plant.
• Fast-acting with rapid absorption
• Provide quick pain relief & continuous lubrication
• Designed to restore mobility and flexibility
• Anti-inflammatory effect
• Clinically tested effective and safe
• Best to consume with Koyoamine® for better efficacy
• Manufactured in USA

CELADRIN®-PURE is a medically and clinically proven pain management compound developed through a proprietary process of a plant-based cetylated fatty acids complex. CELADRIN®-PURE is an innovative, all-natural ingredient that has been medically shown to reduce inflammation and pain with no side effects. 

Celadrin® systematically enhances and lubricates cell membranes throughout the body providing youthful cell fluidity and elasticity. This includes the enhancement of fluids that cushion your bones and joints to maintain flexibility and mobility so that you can move with ease and pain-free. CELADRIN®-PURE also halts a cascade of inflammation that exacerbates joint function. 

Best to consume with Koyosamine®. The dual action of CELADRIN®-PURE and KOYOSAMINE® HCL provides a faster and more effective solution in building joint cartilage, rapidly ease inflammation, and restore the entire joint area.

Clinical Studies I

1. Subjects with moderate OA showed significant improvement in their functional efficacy and improvement in their knee pain after 8 week supplementation of 832mg/d Celadrin®. [UCLA School of Medicine, JK Udani et al. Annual Natural Supplements: Evidence-based Update Medical Conference]

Significant improvement in the distance walked in 6 minutes in the Celadrin® treated group at 2 weeks, 4 weeks, and 8 weeks; while the result for the placebo group was deteriorating.

Average pain severity decreased significantly in the Celadrin® group on all 4 VAS items after 2 weeks and was statistically superior across all VAS items at 8 weeks compared to the subjects who received placebo.

Clinical Studies II

2. Patients with chronic OA showed significant improvement in knee reflexion and osteoarthritis score after  68-day supplementation of 2100 mg/d Celadrin®. [Journal of Rheumatology 2002, 29, 1708-12]

After 68 days, patients treated with CFA exhibited significant improvement in knee flexion (10.1o) compared to placebo (1.1o).

Significant reduction in the pain category (p < 0.049) and the total category (p<0.055) in LAI score by day-68 suggested an improvement of knee OA in the CFA group compared to placebo.